Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma

Pier Luigi Zinzani, Armando Santoro, Arturo Chiti, Secondo Lastoria, Antonio Pinto, Lugi Rigacci, Giovanni Barosi, Martina Pennisi, Paolo Corradini

Research output: Contribution to journalArticle

Abstract

Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy. However, uncertainties still remain on the optimal use of these agents in refractory Hodgkin disease. A panel of experts was convened to produce a consensus document aimed at providing practice recommendations for the optimal use of PD-1 blocking antibodies in cHL, especially on pretreatment selection and evaluation of cHL patients' response and treatment length, management of PD-1 blockade therapy-treated patients, evaluation and management of toxicity. Our hope is that these recommendations might help hematologists to improve optimal management of patients with pretreated cHL.

Original languageEnglish
Pages (from-to)1204-1213
Number of pages10
JournalLeukemia and Lymphoma
Volume60
Issue number5
DOIs
Publication statusPublished - May 2019

Fingerprint

Hodgkin Disease
Blocking Antibodies
Stem Cell Transplantation
Therapeutics
Uncertainty
Recurrence

Cite this

Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. / Zinzani, Pier Luigi; Santoro, Armando; Chiti, Arturo; Lastoria, Secondo; Pinto, Antonio; Rigacci, Lugi; Barosi, Giovanni; Pennisi, Martina; Corradini, Paolo.

In: Leukemia and Lymphoma, Vol. 60, No. 5, 05.2019, p. 1204-1213.

Research output: Contribution to journalArticle

Zinzani, Pier Luigi ; Santoro, Armando ; Chiti, Arturo ; Lastoria, Secondo ; Pinto, Antonio ; Rigacci, Lugi ; Barosi, Giovanni ; Pennisi, Martina ; Corradini, Paolo. / Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 5. pp. 1204-1213.
@article{b253ab28121a4907b051008edd617b05,
title = "Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma",
abstract = "Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy. However, uncertainties still remain on the optimal use of these agents in refractory Hodgkin disease. A panel of experts was convened to produce a consensus document aimed at providing practice recommendations for the optimal use of PD-1 blocking antibodies in cHL, especially on pretreatment selection and evaluation of cHL patients' response and treatment length, management of PD-1 blockade therapy-treated patients, evaluation and management of toxicity. Our hope is that these recommendations might help hematologists to improve optimal management of patients with pretreated cHL.",
author = "Zinzani, {Pier Luigi} and Armando Santoro and Arturo Chiti and Secondo Lastoria and Antonio Pinto and Lugi Rigacci and Giovanni Barosi and Martina Pennisi and Paolo Corradini",
year = "2019",
month = "5",
doi = "10.1080/10428194.2018.1519808",
language = "English",
volume = "60",
pages = "1204--1213",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma

AU - Zinzani, Pier Luigi

AU - Santoro, Armando

AU - Chiti, Arturo

AU - Lastoria, Secondo

AU - Pinto, Antonio

AU - Rigacci, Lugi

AU - Barosi, Giovanni

AU - Pennisi, Martina

AU - Corradini, Paolo

PY - 2019/5

Y1 - 2019/5

N2 - Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy. However, uncertainties still remain on the optimal use of these agents in refractory Hodgkin disease. A panel of experts was convened to produce a consensus document aimed at providing practice recommendations for the optimal use of PD-1 blocking antibodies in cHL, especially on pretreatment selection and evaluation of cHL patients' response and treatment length, management of PD-1 blockade therapy-treated patients, evaluation and management of toxicity. Our hope is that these recommendations might help hematologists to improve optimal management of patients with pretreated cHL.

AB - Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy. However, uncertainties still remain on the optimal use of these agents in refractory Hodgkin disease. A panel of experts was convened to produce a consensus document aimed at providing practice recommendations for the optimal use of PD-1 blocking antibodies in cHL, especially on pretreatment selection and evaluation of cHL patients' response and treatment length, management of PD-1 blockade therapy-treated patients, evaluation and management of toxicity. Our hope is that these recommendations might help hematologists to improve optimal management of patients with pretreated cHL.

U2 - 10.1080/10428194.2018.1519808

DO - 10.1080/10428194.2018.1519808

M3 - Article

VL - 60

SP - 1204

EP - 1213

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -